Craft

Kyverna Therapeutics

Stock Price

$5.3

2024-10-29

Market Capitalization

$230.8 M

2024-10-29

Kyverna Therapeutics Summary

Company Summary

Overview
Kyverna Therapeutics is a pharmaceutical company that generates treatments and potential cures for autoimmune diseases. It develops a therapeutic platform that combines T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases.
Type
Public
Status
Active
Founded
2018
HQ
Emeryville, CA, US | view all locations
Website
https://kyvernatx.com/
Cybersecurity rating
Sectors

Key People

  • Peter Maag, Chief Executive Officer

    LocationsView all

    1 location detected

    • Emeryville, CA HQ

      United States

      5980 Horton St #550

    Kyverna Therapeutics Financials

    Summary Financials

    Net income (Q1, 2026)
    ($39.7M)
    Cash (Q1, 2026)
    $32.2M
    EBIT (Q1, 2026)
    ($41.4M)
    Enterprise value
    $135.5M

    Footer menu